References
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497. https://doi.org/10.1016/S0140-6736(20)30183-5.
Singh S, McNab C, Olson RM, Bristol N, Nolan C, Bergstrøm E, et al. How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic. Lancet. 2021. https://doi.org/10.1016/S0140-6736(21)01897-3.
Valencia DN. Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus. 2020. https://doi.org/10.7759/CUREUS.7386.
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020. https://doi.org/10.3389/FCIMB.2020.587269.
Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16:240–6. https://doi.org/10.1007/S12519-020-00345-5.
Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel coronavirus infection in hospitalised infants under 1 year of age in China. JAMA. 2020;323:1313–4. https://doi.org/10.1001/JAMA.2020.2131.
Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T. Coronavirus disease 2019 in children—United States, February12–April 2 2020. MMWR. 2020;69:422–6. https://doi.org/10.15585/MMWR.MM6914E4.
Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355–68. https://doi.org/10.1097/INF.0000000000002660.
de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of general practitioners research and surveillance centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20:1034–42. https://doi.org/10.1016/S1473-3099(20)30371-6.
Dawood FS, Porucznik CA, Veguilla V, Stanford JB, Duque J, Rolfes MA, et al. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. JAMA Pediatr. 2021. https://doi.org/10.1001/JAMAPEDIATRICS.2021.4217.
American Academy of Pediatrics. Children and COVID-19: state-level data report 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Accessed 8 Mar 2022.
Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179:1029–46. https://doi.org/10.1007/S00431-020-03684-7.
Posfay-Barbe KM, Wagner N, Gauthey M, Moussaoui D, Loevy N, Diana A, et al. COVID-19 in children and the dynamics of infection in families. Pediatrics. 2020. https://doi.org/10.1542/PEDS.2020-1576.
Hobbs CV, Martin LM, Kim SS, Kirmse BM, Haynie L, McGraw S, et al. Factors associated with positive SARS-CoV-2 test results in outpatient health facilities and emergency departments among children and adolescents aged. MMWR. 2020;69:1925–9. https://doi.org/10.15585/MMWR.MM6950E3.
Schwierzeck V, König JC, Kühn J, Mellmann A, Correa-Martínez CL, Omran H, et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 in a pediatric dialysis unit. Clin Infect Dis. 2021;72:265–70. https://doi.org/10.1093/CID/CIAA491.
Krass P, Zimbrick-Rogers C, Iheagwara C, Ford CA, Calderoni M. COVID-19 outbreak among adolescents at an inpatient behavioral health hospital. J Adolesc Health. 2020;67:612–4. https://doi.org/10.1016/J.JADOHEALTH.2020.07.009.
Brown NE, Bryant-Genevier J, Bandy U, Browning CA, Berns AL, Dott M, et al. Antibody responses after classroom exposure to teacher with coronavirus disease, March 2020. Emerg Infect Dis. 2020;26:2263–5. https://doi.org/10.3201/EID2609.201802.
Macartney K, Quinn HE, Pillsbury AJ, Koirala A, Deng L, Winkler N, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. Lancet Child Adolesc Health. 2020;4:807–16. https://doi.org/10.1016/S2352-4642(20)30251-0.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–95. https://doi.org/10.1111/APA.15270.
Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53:371. https://doi.org/10.1016/J.JMII.2020.02.011.
Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021;5:e12–3. https://doi.org/10.1016/S2352-4642(21)00066-3.
Parri N, Magistà AM, Marchetti F, Cantoni B, Arrighini A, Romanengo M, et al. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian pediatric research networks. Eur J Pediatr. 2020;179:1315. https://doi.org/10.1007/S00431-020-03683-8.
Yock-Corrales A, Lenzi J, Ulloa-Gutiérrez R, Gómez-Vargas J, Antúnez-Montes OY, Rios Aida JA, et al. High rates of antibiotic prescriptions in children with COVID-19 or multisystem inflammatory syndrome: a multinational experience in 990 cases from Latin America. Acta Paediatr. 2021;110:1902. https://doi.org/10.1111/APA.15847.
Buonsenso D, Riitano F, Valentini P. Pediatric inflammatory multisystem syndrome temporally related with SARS-CoV-2: immunological similarities with acute rheumatic fever and toxic shock syndrome. Front Pediatr. 2020;8:574. https://doi.org/10.3389/FPED.2020.00574.
Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259–69. https://doi.org/10.1001/JAMA.2020.10369.
Urrunaga-Pastor D, Herrera-Añazco P, Uyen-Cateriano A, Toro-Huamanchumo CJ, Rodriguez-Morales AJ, Hernandez AV, et al. Prevalence and factors associated with parents’ non-intention to vaccinate their children and adolescents against COVID-19 in Latin America and the Caribbean. Vaccines. 2021;9:1303. https://doi.org/10.3390/VACCINES9111303.
Moss WJ, Gostin LO, Nuzzo JB. Pediatric COVID-19 vaccines: what parents, practitioners, and policy makers need to know. JAMA. 2021. https://doi.org/10.1001/JAMA.2021.20734.
Goldschmidt K. COVID-19 vaccines for children: the essential role of the pediatric nurse. J Pediatr Nurs. 2021;57:96. https://doi.org/10.1016/J.PEDN.2020.12.004.
Choi SH, Jo YH, Jo KJ, Park SE. Pediatric and parents’ attitudes towards COVID-19 vaccines and intention to vaccinate for children. J Korean Med Sci. 2021;36:1–12. https://doi.org/10.3346/JKMS.2021.36.E227.
Hadj HI. COVID-19 vaccines and variants of concern: a review. Rev Med Virol. 2021. https://doi.org/10.1002/RMV.2313.
Talukder A, Kalita C, Neog N, Goswami C, Sarma MK, Hazarika I. A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review. Zeitschrift Für Naturforschung C. 2022. https://doi.org/10.1515/ZNC-2021-0301.
Pan American Health Organization (PAHO). Vacunacion contra COVID-19 en las Americas 2021. https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion-es.asp. Accessed 8 Mar 2022.
Moraga-Llop F. Vacunación frente a la COVID-19 en los adolescentes. Una realidad Vacunas. 2021;22:135–7. https://doi.org/10.1016/J.VACUN.2021.05.003.
Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review. Vaccines. 2021;9:1102. https://doi.org/10.3390/VACCINES9101102/S1.
FDA. FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age n.d. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age. Accessed 8 Mar 2022.
Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021;385:239–50. https://doi.org/10.1056/NEJMOA2107456.
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46. https://doi.org/10.1056/NEJMoa2116298.
Xia SL, Zhang YT, Wang YX, Wang H, Yang YK, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2022;22:196–208. https://doi.org/10.1016/S1473-3099(21)00462-X.
Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, et al. Safety and immunogenicity of a recombinant adenovirus type-5–vectored coronavirus disease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged ≥6 years: a randomised, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis. 2021. https://doi.org/10.1093/CID/CIAB845.
Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021. https://doi.org/10.1016/S1473-3099(21)00319-4.
Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2109522.
REUTERS. Factbox: countries vaccinating children against COVID-19 | Reuters 2021. https://www.reuters.com/business/healthcare-pharmaceuticals/countries-vaccinating-children-against-covid-19-2021-06-29/. Accessed 8 Mar 2022.
Saciuk Y, Kertes J, Shamir Stein N, Ekka ZA. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis. 2022;225:30–3. https://doi.org/10.1093/INFDIS/JIAB556.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–76. https://doi.org/10.1016/S0140-6736(21)02717-3.